Given that precision medicine and KRAS inhibitors are usually administered in the context of stage IV NSCLC, we asked whether KRAS mutant-specific dependency on the pathways described above persists in established NSCLC tumors and cell lines, conferring isoform-specific vulnerabilities (Fig. 4A). Here, KRAS is linked to non-small cell lung carcinoma.